Tokyo, June 29 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062085) titled 'Liquid Biopsy for Predicting Treatment Response and Prognosis in Pancreatic Cancer Patients Receiving Preoperative Therapy' on June 28.
Study Type:
Observational
Primary Sponsor:
Institute - Kagawa University
Condition:
Condition - Pancreatic cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To evaluate whether KRAS gene mutations detected by liquid biopsy can predict the response to neoadjuvant therapy in patients with pancreatic cancer undergoing surgical resection. In addition, this study aims to investigate whether longitudinal monitoring of KRAS mutations can serve as a biomarker for postoperative recurrence and prognosis.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 20
years-old
Gender - Male and Female
Key inclusion criteria - Participants must meet all of the following criteria:
Clinically diagnosed with pancreatic cancer.
Scheduled to undergo surgical resection.
Aged 20 years or older and younger than 85 years at the time of registration.
Adequate major organ function confirmed by examinations performed within 2 weeks prior to registration.
Key exclusion criteria - Presence of severe comorbidities, including interstitial pneumonia or pulmonary fibrosis, renal failure, hepatic failure, uncontrolled diabetes mellitus, or uncontrolled hypertension.
Presence of active multiple primary cancer(s).
Presence of active multiple primary cancer(s) with a disease-free interval of less than 5 years.
Target Size - 220
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2020 Year 05 Month 22 Day
Date of IRB - 2020 Year 05 Month 22 Day
Anticipated trial start date - 2020 Year 05 Month 22 Day
Last follow-up date - 2027 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070926
Disclaimer: Curated by HT Syndication.
